Could a Weight-Loss pill help teens with type 2 diabetes?

NCT ID NCT04881799

Ongoing Disease control Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests the drug phentermine/topiramate (Qsymia) in 13 adolescents aged 12-20 who have both obesity and type 2 diabetes. The drug is already approved for weight loss in adults. The study aims to see if it can safely lower body mass index (BMI) and improve blood sugar control over six months. Participants receive either the drug or a placebo pill.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Phentermine/Topiramate (Qsymia)
What this could lead to: If it works, this could offer a new treatment option for teens with type 2 diabetes and obesity, helping them lose weight and better manage their diabetes.
What could go wrong: This is a very early, small trial with only 13 participants, so results may not apply widely. The drug can cause side effects like dizziness, dry mouth, and tingling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEDIATRIC OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder Pediatric Obesity type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PEDIATRIC OBESITY

Contacts and locations

Locations

University of Minnesota

Minneapolis, Minnesota, 55414, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.